Obesity Market to Grow Positively at a Paltry CAGR During the Study Period, DelveInsight | ERX Pharmaceuticals, Amgen, Allysta Pharmaceuticals, Empros Pharma, Innovent Biologics, Pfizer, Boehringer Ingelheim, MedImmune LLC, Scohia Pharma, Eli Lilly and Co

DelveInsight's "Obesity - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Obesity market share of the individual therapies, current and forecasted Obesity market size from 2020 to 2034 segmented by seven major markets. The report also offers current Obesity therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Obesity market.
Download our report @ https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key highlights from the obesity market report:
In 2023, the United States held the largest share of the obesity market, exceeding USD 2,000 million, compared to the combined markets of EU4 countries (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Key obesity companies working in the obesity market are ERX Pharmaceuticals, Amgen, Allysta Pharmaceuticals, Empros Pharma, Innovent Biologics, Pfizer, Boehringer Ingelheim, MedImmune LLC, Scohia Pharma, Eli Lilly and Company, and others.
Obesity is classified as a chronic disease characterized by complex, multifactorial factors and excess body fat, impacting health beyond mere body size. It often manifests metabolically, affecting overall well-being.
The US FDA has approved several long-term treatments for obesity, including XENICAL (orlistat), QSYMIA (phentermine-topiramate), CONTRAVE (naltrexone-bupropion), SAXENDA (liraglutide), WEGOVY (semaglutide), and IMCIVREE (setmelanotide). In November 2023, the FDA also approved ZEPBOUND (tirzepatide) from Eli Lilly and Company, a new injection that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) hormone receptors.
Among these therapies, WEGOVY (semaglutide) and ZEPBOUND (tirzepatide) are projected to generate the highest revenue in the US. Additionally, Pfizer's recent Phase IIb clinical trial results for its oral GLP-1 receptor agonist, danuglipron (PF-06882961), demonstrated significant weight loss in adults with obesity, meeting its primary endpoint.
Recent years have seen a surge in novel obesity treatments, including drug combinations such as SAXENDA (liraglutide), XENICAL (orlistat), WEGOVY (semaglutide), and QSYMIA (phentermine-topiramate). The dynamics of the obesity market are expected to shift as global companies develop new therapies for weight management. Major players like Novo Nordisk, Eli Lilly, and Boehringer Ingelheim are at the forefront of this effort.
According to DelveInsight, the United States accounted for about 60% of the total obesity cases in the 7MM in 2023. The prevalence of obesity in the US is rising, with the highest rates observed in adults over 19 and children aged 5-19. Both groups are expected to see moderate annual increases in obesity rates.
In June 2024, researchers at Children's Hospital of Philadelphia (CHOP) revealed mechanisms behind a molecule's role in regulating insulin sensitivity, potentially paving the way for a new therapeutic target for obesity-related type 2 diabetes.
In June 2024, Novo Nordisk and Eli Lilly dominated the obesity market, with Novo Nordisk generating $6.3 billion and Eli Lilly $2.3 billion in sales from their weight-loss drugs in Q1 2024.
In June 2024, the US House Ways and Means Committee proposed a strategy for Medicare to cover GLP-1 weight-loss drugs like Wegovy and Zepbound.
Obesity Overview
Obesity arises from a combination of genetic predispositions and environmental factors. Severe and early-onset monogenic forms of obesity are often linked to gene mutations affecting the leptin-melanocortin pathway. Key genes involved include LEPR (which encodes the leptin receptor), POMC (pro-opiomelanocortin), MC4R (melanocortin-4 receptor), NTRK2 (tropomyosin receptor kinase B receptor), and SIM1 (single-minded 1 transcription factor). The most apparent sign of obesity is excess adipose tissue, typically assessed through anthropometric measurements. Common symptoms include stretch marks, high blood pressure, and a BMI over 30 kg/m².

Early diagnosis and intervention are crucial for effective obesity treatment. Diagnosis involves a comprehensive assessment of weight status using various tools and tests, such as body mass index (BMI), waist circumference measurements, physical examinations, and laboratory tests to identify related comorbidities.

The obesity report offers a comprehensive overview of the disease's pathophysiology, diagnostic methods, and treatment algorithms. It also includes a real-world example of a patient's journey, from the initial symptoms and diagnosis to the full treatment process.
To know more about obesity, visit: https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Obesity Epidemiological Insights
According to DelveInsight's estimates, the United States had the highest number of prevalent obesity cases among the 7MM in 2023.
The analysis indicates that adults represented the majority of those seeking treatment for obesity during this period. Additionally, treatment rates for children were notably lower compared to adults across various countries.
Within the EU4 and the UK, the United Kingdom had the highest number of treated obesity cases among adults in 2023, followed by Germany.
Obesity Market
The United States holds approximately 80% of the global obesity market, surpassing the combined market size of Germany, Spain, Italy, France (EU4), the United Kingdom, and Japan. By 2034, WEGOVY (semaglutide) and ZEPBOUND (tirzepatide) are projected to capture significant market shares across the seven major markets. Germany is expected to have the second-largest obesity market size among the 7MM during the forecast period from 2024 to 2034. The obesity market is anticipated to experience substantial growth during this period, driven by the introduction of new therapies and the rising prevalence of obesity.
Discover more about Obesity treatment therapies in the pipeline @ https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Obesity Market
Novo Nordisk
Eli Lilly and Company
MedImmune
Boehringer Ingelheim
Raziel Therapeutics
Altimmune
Saniona
YSOPIA Bioscience
Innovent Biologics
Glaceum
Shionogi
Aardvark Therapeutics
NuSirt Biopharma
Novartis
CSPC Baike (Shandong) Biopharmaceutical
Jiangsu HengRui Medicine
Carmot Therapeutics
Pfizer
Sciwind Biosciences
Empros Pharma
And others
To understand key companies related to the Obesity Market, get a snapshot of the Obesity Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Obesity Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Obesity Companies: Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma, and others
Therapeutic Assessment: Obesity current marketed and emerging therapies
Obesity Market Dynamics: Obesity market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Obesity Market Access and Reimbursement
Table of Contents
1. Obesity Market Key Insights
2. Obesity Market Report Introduction
3. Obesity Market Overview at a Glance
4. Obesity Market Executive Summary
5. Disease Background and Overview
6. Obesity Treatment and Management
7. Obesity Epidemiology and Patient Population
8. Patient Journey
9. Obesity Emerging Drugs
10. 7MM Obesity Market Analysis
11. Obesity Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Obesity Market Drivers
15. Obesity Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.